RECRUITING

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

Description

This study aims at quantifying the accuracy of a self-administered fingerstick based glucose tolerance test (GTT@Home) respect to the gold-standard in-clinic venous plasma measures during the oral glucose tolerance test (OGTT) across a wide range of glycemic values in people at risk for clinical type 1 diabetes (T1D) (carriers of at least one islet autoantibody) or with new onset Stage 3 T1D within 100 days from the diagnosis.

Conditions

Type 1 Diabetes
Talk to us

Related Conditions:

Type 1 Diabetes

Study Overview

On this page

Study Details

Study overview

This study aims at quantifying the accuracy of a self-administered fingerstick based glucose tolerance test (GTT@Home) respect to the gold-standard in-clinic venous plasma measures during the oral glucose tolerance test (OGTT) across a wide range of glycemic values in people at risk for clinical type 1 diabetes (T1D) (carriers of at least one islet autoantibody) or with new onset Stage 3 T1D within 100 days from the diagnosis.

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

Condition
Type 1 Diabetes
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale University Pediatric and Adult Diabetes Clinic, New Haven, Connecticut, United States, 06520

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Body weight ≥43 kg
  • * Presence of at least one islet autoantibody and/or≥ diagnosis of clinical T1D within 100 days.
  • * Documentation of the presence at least 1 islet autoantibody
  • * If participants meet ADA diagnostic criteria for Stage 3 type 1 diabetes, they will be eligible if the enrollment occurs within 100 days from the diagnosis and are at least 12 years old.
  • * Participants must be in good general health without other acute (e.g. infectious disease) febrile or chronic illnesses (e.g. uncontrolled asthma requiring high steroid doses, chronic arthritis) that in the judgment of the investigator could jeopardize participant safety or interfere with the study,
  • * Ability to give consent/assent
  • * Able to understand written and spoken English
  • * Currently pregnant or becomes pregnant during the study
  • * Participants on sodium glucose cotransporter inhibitors (SGLTi).
  • * Donated blood in the past 8 weeks.

Ages Eligible for Study

8 Years to 45 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Yale University,

Alfonso Galderisi, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2027-09